Bilaal.Raja
Company record

MDGL  MADRIGAL PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30, as filed 2026-07-30 and not restated since.
Healthcare

Scale

Market cap
$12.5bn
Revenue TTM
$1.3bn
Net income TTM
$-325m
Free cash flow
$-206m
Composite score
44.7
Sector rank
#616

Valuation

P / E
EV / EBITDA
EV / sales
9.4
FCF yield
-1.64%
Yield vs 10-yr
-7.32pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-25.3%
EBITDA margin
-25.0%
ROE
-62.1%
ROIC
-1,252.1%
Revenue growth
149.0%

Insider activity, last 90 days

Net open-market
$-2.23m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The increase was driven by increased demand for Rezdiffra in the United States in 2026. Cost of Sales Cost of sales were incurred as a result of sales of Rezdiffra and includes non-cash stock-based compensation expense for employees dedicated to the production of Rezdiffra. For the three months ended June 30, 2026, we recorded $40.0 million of cost of sales compared to $9.1 million in the corresponding period in 2025. Research and development expenses increased by $37.1 million in the 2026 period, primarily due to one-time upfront business development expenses of $25.0 million and an $8.0 million increase in compensation and benefit-related expenses and stock-based compensation expense as a …MADRIGAL PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →